Stem cell mobilization
Fibrosis reduction
New blood vessel growth
Tissue oxygen 8-10× higher
Non-healing wounds, skin breakdown, and tissue necrosis in irradiated areas.
Bone death in irradiated fields — most commonly the mandible after head/neck cancer treatment.
Rectal inflammation after radiation for prostate, cervical, or rectal cancer. Causes rectal bleeding, diarrhea, urgency.
Chronic bladder inflammation following pelvic radiation. Causes blood in urine, urinary frequency, urgency, pain.
Radiation therapy targets cancer cells, but it also damages the blood vessels and normal tissue in the treatment field. Over time — months to years after treatment — this creates a progressive cycle of tissue hypoxia, fibrosis, and breakdown that's known as late radiation tissue injury (LRTI).
The irradiated tissue becomes chronically oxygen-starved. Normal healing can't occur. Patients develop bleeding, pain, ulceration, and tissue necrosis that conventional treatments often can't resolve.
Treatment frequency
Total sessions
Session duration
Treatment pressure
Sources: J Clin Med 2024; Int J Radiat Oncol Biol Phys 2012
HBOT controlled bleeding in 84% of patients; durable freedom from hematuria in 96%
55% complete resolution of hematuria (95% CI 51-59%)
2024 meta-analysis: 89.9% of patients achieved symptom improvement
Sources: PMC 2024; StatPearls 2023; Undersea Hyperb Med 2022; ECHM Consensus 2017
Prophylactic HBOT reduces ORN risk after dental extraction in irradiated fields
RR 4.2 for wound breakdown prevention after ORN surgery
Cochrane Review: RR 1.3 for mucosal coverage (95% CI 1.1-1.6, NNT 5)
Sources: Cochrane Database Syst Rev 2016; Front Oncol 2023
Complete resolution of bleeding in 50-78% of refractory cases
Prospective study: 89% symptom alleviation, sustained at 6-12 months
Cochrane Review: RR 1.72 for improvement/cure (95% CI 1.0-2.9, NNT 5)
Often, yes. HBOT addresses the underlying hypoxia that other treatments can't fix. Many of our patients have tried medications, cauterization, or formalin before HBOT — and still achieve significant improvement.
Yes. Radiation tissue injury is FDA-approved and covered by Medicare and most commercial insurers. We verify your benefits before treatment.
If you received >50 Gy to your mandible, prophylactic HBOT significantly reduces your risk of osteoradionecrosis. The Marx protocol involves 20 pre-op + 10 post-op sessions for high-risk patients.
HBOT is used for late radiation effects, typically after cancer treatment is complete. Extensive research shows no evidence that HBOT promotes cancer recurrence. We coordinate with your oncology team.
There's no upper time limit. HBOT has helped patients decades after their original radiation therapy. Late radiation injury is progressive — even if symptoms appeared years ago, HBOT can still promote healing.